{"filings":[{"id":1747839,"accession_number":"0001193125-26-308899","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-07-20T20:00:14+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Damora Therapeutics completes redomestication from Delaware to Cayman Islands","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redomestication effective July 16, 2026; each common share converted 1:1 into ordinary shares of Cayman company.","New CUSIP G2646Y104; ordinary shares continue trading on Nasdaq under symbol DMRA as of July 20, 2026.","No change in business, management, obligations, assets, or liabilities; company remains a U.S. corporation for tax purposes.","Stockholders approved the redomestication at a special meeting on February 9, 2026.","Company also entered into indemnification agreements with directors and executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1110796,"accession_number":"0001193125-26-274093","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-06-17T20:00:15+00:00","items":["5.07"],"status":"ready","headline":"Damora Therapeutics shareholders elect directors, approve say-on-pay and E&Y ratification at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.","Advisory say-on-pay approved: 51,401,988 for, 3,546 against, 27,018 abstain.","Say-on-frequency: one-year option received 50,913,167 votes; Board adopts annual frequency.","Ratified Ernst & Young as auditor for FY2026: 54,977,317 for, 5,640 against, 26,981 abstain.","Quorum of 55,009,938 shares out of 60,303,212 outstanding was represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95541,"accession_number":"0001193125-26-203913","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Damora Therapeutics CFO Lori Firmani to depart May 1; Brian Burkavage appointed principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.","Firmani receives lump-sum salary continuation, prorated bonus, $6K HSA, and full equity acceleration.","Brian Burkavage, current SVP Finance, appointed principal financial and accounting officer effective May 1.","Burkavage previously SVP Finance and CAO at IO Biotech; CPA with 11 years at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95540,"accession_number":"0001193125-26-163909","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Damora Therapeutics dismisses EY Denmark auditor, appoints EY US","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.","No disagreements or reportable events occurred in FY 2024 or 2025 or the subsequent interim period.","EY Denmark's 2024 report included a going-concern explanatory paragraph.","Company provided EY Denmark with disclosures; EY Denmark's letter to SEC filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108682,"accession_number":"0001193125-26-118699","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.","Three directors (Munshi, Goldfischer, Dallas) resigned March 23; not due to disagreements.","New directors: Cameron Turtle (CEO, Spyre Therapeutics) and Mike Landsittel (ex-CFO, Blueprint Medicines).","Peter Harwin named Chairman of the Board.","Jarrett receives $695k base salary, 55% target bonus, 500k RSUs and 1.5M stock options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108687,"accession_number":"0001193125-26-099404","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.","Preliminary cash and cash equivalents ~$535M as of Feb 28, 2026, including ~$316M from Feb 2026 public offering.","DMR-001 (anti-mutCALR antibody) IND/CTA on track for mid-2026; proof-of-concept data expected mid-2027.","DMR-002 IND/CTA planned for H2 2026; DMR-003 IND/CTA in 2027.","Acquisition of privately held Damora closed Nov 2025 with ~$285M private investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108686,"accession_number":"0001193125-26-046817","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.","Net proceeds of approximately $295.9M after underwriting discounts and expenses.","Proceeds intended to fund operations into Phase 3 development of DMR-001.","Underwriting agreement with Jefferies LLC and Leerink Partners LLC; closing expected February 12, 2026.","Offering was made under an automatic shelf registration statement on Form S-3 (File No. 333-293343)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108685,"accession_number":"0001193125-26-043741","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["5.02","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.","Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.","Automatic conversion of Series C Preferred yields ~42M new shares; total outstanding rises from ~1.6M to ~43.6M.","Shareholders also approve 2026 Equity Incentive Plan and Employee Stock Purchase Plan.","Separation agreement for Schambye includes lump-sum base salary continuation, pro-rated bonus, and full equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108684,"accession_number":"0001193125-26-009812","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galecto furnishes corporate slide deck for J.P. Morgan Healthcare Conference; no new material disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 with a corporate presentation (January 2026) as Exhibit 99.1.","No specific financial, pipeline, or operational numbers were included in the exhibit text provided.","Presentation is for meetings at the 44th Annual J.P. Morgan Healthcare Conference starting Jan 12, 2026.","Investors cannot derive new material facts from the limited text available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108683,"accession_number":"0001193125-26-003490","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.","Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.","Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.","Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125129,"accession_number":"0001193125-25-312912","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K/A","filed_at":"2025-12-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.","Authorized shares revised to 43,882 from incorrectly stated 43,855; no other terms changed.","Amendment amends 8-K originally filed Nov 10, 2025; restated certificate attached as Exhibit 3.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125130,"accession_number":"0001193125-25-273342","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.","Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.","Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.","Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.","Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159772,"accession_number":"0000950170-25-088168","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto stockholders approve director elections, preferred stock conversion, and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.","Preferred stock conversion approved: 226,407 for, 15,099 against, 800 abstain; 435,515 broker non-votes.","Ratification of EY as auditor approved: 660,974 for, 16,319 against, 528 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194807,"accession_number":"0000950170-24-114481","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galecto appoints Dr. Amy Wechsler to Board of Directors effective October 11, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven members; Wechsler appointed as Class I director with term through 2027 annual meeting.","Wechsler is board-certified in dermatology and psychiatry and serves on the Bausch Health board.","She holds an M.D. from Cornell University Medical College and an M.B.A. from Columbia Business School (2024).","Wechsler is independent under Nasdaq standards and will receive standard non-employee director compensation and equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194806,"accession_number":"0000950170-24-113091","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","2.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.","BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia (AML).","Carl Goldfischer, Galecto's Chairman, also serves as Executive Chairman of Bridge Medicines (related-party transaction).","Pro forma impact: cash reduced by $2.68M; total consideration valued at stock issuance; assumes liabilities.","Stockholder approval required for conversion of preferred shares; Bridge Medicines restricted from selling shares for 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211099,"accession_number":"0000950170-24-107580","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.","The deficiency notice is now closed; no further action required on this matter.","Shares continue trading on Nasdaq Capital Market under ticker GLTO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211098,"accession_number":"0000950170-24-105533","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto completes 1-for-25 reverse stock split; post-split shares at 1,248,266","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective August 29, 2024; every 25 shares converted to 1 share.","Computershare confirms total outstanding shares post-split: 1,248,266.","Fractional shares resulting from the reverse split were rounded up to the nearest whole share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211097,"accession_number":"0000950170-24-103957","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.","Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.","Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.","New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229615,"accession_number":"0000950170-24-076186","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto shareholders approve reverse stock split and elect Anne Prener to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Anne Prener elected with 10,651,770 for, 711,618 withheld; 5,840,793 broker non-votes.","Reverse stock split approved (ratio 1:4 to 1:25, board to decide within one year): 15,283,182 for, 1,830,713 against.","Ratification of EY as auditor for FY2024 passed with 16,927,703 for, 197,148 against.","Total shares entitled to vote: 27,112,697; 17,204,181 present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248141,"accession_number":"0000950170-24-036391","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.","Received 180-day extension until September 22, 2024 to regain $1.00 minimum bid price compliance.","Company had failed to meet bid price requirement by March 25, 2024 compliance date.","GLTO continues trading under same symbol; reverse stock split is under consideration.","If not compliant by September 22, Nasdaq may delist; company could appeal to hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265605,"accession_number":"0000950170-23-072258","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galecto reports positive Phase 2a myelofibrosis data; fibrosis reduction in 6 of 10 evaluable patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.","All 6 patients with fibrosis reduction maintained stable hematological parameters (hemoglobin, WBC, platelets).","One patient achieved ≥35% spleen volume reduction; two reduced Total Symptom Score >50%; one had anemia response.","Four patients entered extension due to clinical benefit; one on treatment >30 months; GI adverse events manageable.","Company will not decide on further GB2064 trials until completion of strategic alternative process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265604,"accession_number":"0000950170-23-054508","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.","Galecto will not initiate Part B of GALLANT-1, reallocating resources to severe liver diseases as part of strategic alternative process.","Two severe dose-limiting skin reactions occurred at 200 mg dose; no such reactions at the recommended 100 mg dose level.","Galecto to supply GB1211 for an investigator-initiated Phase 2 trial at Providence Portland Medical Center expected in early 2024.","Company plans to explore external options for partnering/funding further oncology activities for GB1211."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265603,"accession_number":"0000950170-23-051118","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.","Company has until March 25, 2024 to regain compliance with Minimum Bid Price Requirement.","If not cured, Galecto may qualify for a second 180-day period by transferring to Nasdaq Capital Market.","Galecto may consider a reverse stock split to regain compliance, but no assurance of success.","Common stock symbol GLTO continues trading on Nasdaq Global Select Market pending compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282811,"accession_number":"0000950170-23-049919","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["2.05","8.01","5.02","9.01"],"status":"ready","headline":"Galecto explores strategic alternatives; cuts workforce 70%, CMO out","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~29 employees (~70% of headcount) approved Sept 20, 2023.","Estimated restructuring charges of ~$2.8M mostly in Q3 2023; execution substantially complete by Q4 2023.","CMO Bertil Lindmark's position eliminated effective Oct 1, 2023; CEO Hans Schambye assumes duties.","CEO and CFO retention bonuses: CEO up to DKK 2,090,208 for milestones; CFO $183,456 target bonus.","Cash and equivalents $52.1M as of June 30, 2023; no timetable for strategic review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282810,"accession_number":"0000950170-23-042631","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-08-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).","Serious adverse events: 7.8% in GB0139 arm vs 1.4% placebo; worsening IPF observed.","Cash and investments ~$49M as of July 31, 2023; evaluating resource allocation to extend runway into 2025.","Shifting focus to liver diseases; GULLIVER-3 Phase 2a trial of GB1211 expected to start early 2024.","No confirmation of target engagement; galectin-3 levels increased in both arms from day 0 to week 52."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302138,"accession_number":"0000950170-23-028265","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto stockholders elect three Class III directors and ratify EY as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Jayson Dallas, Amit Munshi, and Hans Schambye as Class III directors with 9.9M, 10.5M, and 10.5M votes for, respectively.","Ratified EY Godkendt Revisionspartnerselskab as independent auditor for FY 2023 with 16.0M votes for, 52,661 against.","Broker non-votes of 5.5M on director election; no broker non-votes on auditor ratification.","Total shares present or represented: 16.1M out of 25.7M entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321814,"accession_number":"0000950170-23-007228","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Galecto discloses SVB exposure under $1.5M; no material impact expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDIC took control of Silicon Valley Bank on March 10, 2023 due to liquidity concerns.","Galecto's cash deposits at SVB total less than $1.5 million, excluding FDIC-insured amounts.","Company does not anticipate any material effect on its operating plan or cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321813,"accession_number":"0000950170-23-000283","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Galecto reports $66M cash as of Dec 31, 2022; updates corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Cash, cash equivalents, and investments of approx. $66M as of Dec. 31, 2022.","Updated corporate presentation dated Jan. 2023 furnished as an exhibit; no specific details or material changes described.","No financial or operational guidance provided beyond the cash balance update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339919,"accession_number":"0000950170-22-020535","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.","Part 2 data selected as 'Best of The Liver Meeting' in NASH/NAFLD category.","Preclinical rabbit model: GB1211 significantly reduced inflammation, fibrosis, and fat vs control.","Galecto to host webinar Nov 8, 2022 at 8:00 AM ET to discuss expanded topline data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357226,"accession_number":"0000950170-22-018988","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.","All four fibrosis responders showed stable hemoglobin, WBC, platelets, and spleen volume; no transfusions needed.","Two patients entered extension phase due to clinical benefit as assessed by treating physician.","No treatment-related SAEs in the 5-patient evaluable group; one possible SAE (fall) in entire 16-patient trial.","Company expects top-line results from GULLIVER-2 liver cirrhosis trial in coming weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375816,"accession_number":"0000950170-22-011770","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Galecto stockholders elect two Class II directors and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carl Goldfischer, M.D. elected with 11,025,408 votes for; David Shapiro, M.D. with 11,050,440 votes for.","Ratification of EY Godkendt Revisionspartnerselskab as independent auditor for FY2022: 15,589,293 for, 33,022 against.","15,647,815 shares represented at meeting out of 25,261,832 entitled to vote; 3,360,631 broker non-votes on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394146,"accession_number":"0001564590-22-004414","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.","Non-Executive Chair annual option grant increased from 18,000 to 36,000 shares; other directors remain at 18,000.","Initial equity award of 18,000 options vests over 36 months; annual award vests over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394145,"accession_number":"0001564590-22-002577","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Galecto reports safety and efficacy of GB0139 in COVID-19; 21% mortality reduction in high-risk subgroup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.","Target engagement confirmed: statistically significant reduction in serum galectin-3 (p<0.01).","GB0139-treated patients had significantly greater rate of decline in oxygen requirement vs standard of care.","In high-risk subgroup, 21% mortality reduction observed; company plans co-development for COVID-19.","GALACTIC-1 IPF trial: amendment to reduce target patients, topline expected mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394144,"accession_number":"0001564590-22-000413","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":[],"status":"ready","headline":"Galecto files updated corporate presentation for January 2022 investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation titled 'First-in-class small-molecule anti-fibrotic and anti-cancer agents'.","Filed under Regulation FD; presentation dated January 2022.","No specific new financial or pipeline details disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431419,"accession_number":"0001564590-21-035806","cik":1800315,"company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","form_type":"8-K","filed_at":"2021-07-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Galecto adopts executive Separation Benefits Plan with tiered severance for C-Level officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan covers CEO, CFO, COO, CMO, General Counsel and other designated employees.","Non-Sale termination: CEO receives 15 months base salary; other C-Level get 12 months; prorated bonus and equity vesting during severance period.","Sale Event termination: CEO gets 18 months lump sum; other C-Level get 12 months lump sum; bonus of 150%/100% of target; 100% equity vesting.","Plan supersedes all prior severance agreements and requires a release of claims, non-disparagement, and cooperation as conditions.","Board may amend or terminate plan with 18 months' notice before a Sale Event; post-Sale Event amendments restricted for 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1541291971.0654502,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}